Hiroki Maekawa
Director of Finance/CFO bij KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.
Profiel
Hiroki Maekawa is currently the Chief Financial Officer & Director at Kubota Pharmaceutical Holdings Co. Ltd.
since 2019 and the Chief Financial Officer at Acucela, Inc. since 2018.
Previously, he held positions as the CFO, Director & Head-Investor Relations at SymBio Pharmaceuticals Ltd.
in 2013, and as a Principal at Nippon Life Insurance Co., ASKA Pharmaceutical Co., Ltd., and Sosei Group Corp.
He completed his undergraduate degree in Economics from Doshisha University Faculty of Economics in 1990.
Actieve functies van Hiroki Maekawa
Bedrijven | Functie | Begin |
---|---|---|
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. | Director of Finance/CFO | 01-06-2018 |
ACUCELA INC | Director of Finance/CFO | 01-11-2018 |
Eerdere bekende functies van Hiroki Maekawa
Bedrijven | Functie | Einde |
---|---|---|
ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology ASKA Pharmaceutical Co., Ltd. engages in the manufacture, sale, import, and export of pharmaceuticals, veterinary medicine, quasi-drugs, food, and medical devices. It operates through the Pharmaceutical Business and Other segments. The Pharmaceutical Business segment manufactures and sells medical drugs. The Other segment includes veterinary drugs, clinical testing, and medical devices. The company was founded by Yasohachi Yamaguchi on June 16, 1920 and is headquartered in Tokyo, Japan. | Corporate Officer/Principal | - |
NXERA PHARMA CO., LTD. | Corporate Officer/Principal | - |
Nippon Life Insurance Co.
Nippon Life Insurance Co. Life/Health InsuranceFinance Nippon Life Insurance Co. engages in the provision of life insurance services, agency or administration services to other insurance companies and financial institutions. It also provides the guarantees for liabilities, sale and purchase of government bonds and local government bonds, and sales of investment trust beneficiary securities. The company was founded by Sukesaburo Hirose on July 4, 1889 and is headquartered in Osaka, Japan. | Corporate Officer/Principal | - |
SYMBIO PHARMACEUTICALS LIMITED | Director of Finance/CFO | 03-04-2013 |
Opleiding van Hiroki Maekawa
Doshisha University Faculty of Economics | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
NXERA PHARMA CO., LTD. | Health Technology |
SYMBIO PHARMACEUTICALS LIMITED | Health Technology |
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Nippon Life Insurance Co.
Nippon Life Insurance Co. Life/Health InsuranceFinance Nippon Life Insurance Co. engages in the provision of life insurance services, agency or administration services to other insurance companies and financial institutions. It also provides the guarantees for liabilities, sale and purchase of government bonds and local government bonds, and sales of investment trust beneficiary securities. The company was founded by Sukesaburo Hirose on July 4, 1889 and is headquartered in Osaka, Japan. | Finance |
ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology ASKA Pharmaceutical Co., Ltd. engages in the manufacture, sale, import, and export of pharmaceuticals, veterinary medicine, quasi-drugs, food, and medical devices. It operates through the Pharmaceutical Business and Other segments. The Pharmaceutical Business segment manufactures and sells medical drugs. The Other segment includes veterinary drugs, clinical testing, and medical devices. The company was founded by Yasohachi Yamaguchi on June 16, 1920 and is headquartered in Tokyo, Japan. | Health Technology |
Acucela, Inc.
Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |